BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Rating of “Moderate Buy” by Brokerages

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $365.7857.

ONC has been the subject of a number of research analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $420.00 price target on shares of BeOne Medicines in a research note on Monday, November 17th. Truist Financial set a $400.00 target price on BeOne Medicines in a research report on Monday, November 24th. Royal Bank Of Canada reiterated an “outperform” rating on shares of BeOne Medicines in a report on Wednesday, December 17th. Citigroup raised their price objective on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday, October 3rd.

BeOne Medicines Price Performance

ONC stock opened at $320.30 on Tuesday. The stock’s 50 day moving average is $326.72 and its two-hundred day moving average is $311.96. BeOne Medicines has a 52-week low of $172.67 and a 52-week high of $385.22. The company has a market capitalization of $35.12 billion, a PE ratio of 628.04 and a beta of 0.47. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03.

Insider Buying and Selling at BeOne Medicines

In other news, COO Xiaobin Wu sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $356.02, for a total transaction of $3,560,200.00. Following the completion of the transaction, the chief operating officer directly owned 6,009 shares of the company’s stock, valued at approximately $2,139,324.18. This represents a 62.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John Oyler sold 75,631 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $307.79, for a total value of $23,278,465.49. Following the sale, the chief executive officer owned 24,369 shares in the company, valued at $7,500,534.51. The trade was a 75.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 138,617 shares of company stock valued at $44,632,898. Corporate insiders own 6.62% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

Several large investors have recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC boosted its holdings in shares of BeOne Medicines by 4.1% during the third quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock valued at $436,000 after acquiring an additional 50 shares during the period. Penserra Capital Management LLC lifted its position in BeOne Medicines by 2.7% in the 3rd quarter. Penserra Capital Management LLC now owns 2,981 shares of the company’s stock valued at $1,015,000 after purchasing an additional 79 shares during the last quarter. Allianz Asset Management GmbH boosted its stake in BeOne Medicines by 3.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 3,400 shares of the company’s stock valued at $1,158,000 after purchasing an additional 100 shares during the period. Blue Trust Inc. boosted its stake in BeOne Medicines by 11.7% during the 3rd quarter. Blue Trust Inc. now owns 967 shares of the company’s stock valued at $329,000 after purchasing an additional 101 shares during the period. Finally, Anchor Investment Management LLC bought a new position in BeOne Medicines in the 2nd quarter worth about $26,000. 48.55% of the stock is owned by institutional investors and hedge funds.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.